TANKE BIOSCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 USD | 0.00% |
|
0.00% | -73.32% |
| 02-26 | Tanke Biosciences Corp Appoints Kenneth Marks to the Board of Directors | CI |
| 02-08 | Tanke Biosciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 16.26 | 1.347 |
| Enterprise Value (EV) 1 | 16.22 | 1.393 |
| P/E ratio | -21.5 x | -12.9 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | - | -19,872,416 x |
| FCF Yield | - | -0% |
| Price to Book | -99.9 x | -23.6 x |
| Nbr of stocks (in thousands) | 13,324 | 13,324 |
| Reference price 2 | 1.220 | 0.1011 |
| Announcement Date | 2/8/24 | 2/8/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT 1 | -0.668 | -0.1282 |
| Operating Margin | - | - |
| Earnings before Tax (EBT) 1 | -0.723 | -0.0982 |
| Net income 1 | -0.723 | -0.0982 |
| Net margin | - | - |
| EPS 2 | -0.0567 | -0.007866 |
| Free Cash Flow | - | -0.0701 |
| FCF margin | - | - |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 2/8/24 | 2/8/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Net Debt 1 | - | 0.05 |
| Net Cash position 1 | 0.04 | - |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow | - | -0.07 |
| ROE (net income / shareholders' equity) | - | 133% |
| ROA (Net income/ Total Assets) | - | -328% |
| Assets 1 | - | 0.0299 |
| Book Value Per Share 2 | -0.0100 | -0 |
| Cash Flow per Share 2 | 0.0100 | 0 |
| Capex | - | - |
| Capex / Sales | - | - |
| Announcement Date | 2/8/24 | 2/8/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -73.32% | 845K | |
| +16.63% | 12.02B | |
| +6.55% | 6.21B | |
| +14.80% | 5.13B | |
| -19.13% | 2.74B | |
| +3.80% | 1.95B | |
| -12.27% | 1.29B | |
| -10.05% | 958M | |
| -18.43% | 946M | |
| +28.28% | 889M |
- Stock Market
- Equities
- TNBI Stock
- Financials Tanke Biosciences Corporation
